The Motley Fool Previous Page

3 Humongous Health-Care Stocks This Week

Keith Speights
November 9, 2012

With the market experiencing huge losses this week, you might think that it could be difficult to find health-care stocks to include in a list of humongous performers. It's true that there were many biotech stocks dropping by double-digit percentages. However, the week also brought forth several big gainers. Let's take a look at our humongous health-care stocks of the week.

A rare winner
How does a 28% jump in one week sound? BioMarin Pharmaceuticals (Nasdaq: BMRN  ) even did slightly better than that this week. The company reported phase 3 results for GALNS, its drug for treating Morquio A syndrome. As you might suspect, those results were very good

Morquio A is very rare, affecting 1,000 to 1,500 patients in the U.S. and no more than 3,000 patients worldwide. Patients with Morquio A syndrome have skeletal dysplasia and joint abnormalities that make walking quite difficult. The late-stage study found that patients who took a weekly regimen of GALNS significantly improved how far they could walk over a six-minute period.

BioMarin plans to file for regulatory approval to market the drug in the first quarter of 2013. The company's chances for gaining approval look good in light of the phase 3 results.

Less bad is good
Intermune (Nasdaq: ITMN  ) jumped 19% for the week. The big gains followed the company's third-quarter results announcement.

It's fair to say that expectations have been quite low lately for Intermune. Analysts expected the company to lose $0.84 per share in the quarter. However, Intermune surprised everyone with a loss of only $0.70 per share. The company also reported revenue of $7.5 million, beating analyst estimates of $6.2 million. 

Shareholders hope the improved results mean that Intermune will ultimately be successful with Esbriet, a drug